The clinical trials evaluating the efficacy of this compound in NASH patients produced contradictory results; an initial trial that lasted a year showed a decrease in liver enzymes, lipids, and glucose levels and an increase rate of NASH resolution without fibrosis worsening in treated patients, although this late result was barely significant [ 187 ].
1
—
—